Masayoshi Harigai, MD, PhD is Professor and Chairperson of Department of Rheumatology at Tokyo Women’s Medical University, Tokyo, Japan. He graduated from National Defense Medical College and received PhD from Keio University in 1991. After spending two years as a research fellow in Burnham Institute (former La Jolla Cancer Research Foundation) in San Diego, he came back to Japan and served as Professor of Department of Pharmacovigilance at Graduate School of Tokyo Medical and Dental University between 2007 and 2015. After returning to Tokyo Women’s University in 2015 as an Endowed Professor, he was installed in the present position in 2019.
Professor Harigai is the principal investigator of several large cohort studies for patients with rheumatoid arthritis in Japan, including ORIGAMI, REAL, CORRECT and SECURE. He was the principal investigator of the study group for development of molecular targeting therapy for ANCA-associated vasculitis as well from April 2015 to March 2018. He revised the clinical practice guidelines of ANCA-associated vasculitis in Japan in 2017 and is the current principal investigator of Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS). He has been involved in the analysis of the post-marketing surveillance (PMS) studies of biological DMARDs in Japan as a member of PMS committee of Japan College of Rheumatology.